BridgeBio

BridgeBio

Develops medicines for genetic diseases

About BridgeBio

Simplify's Rating
Why BridgeBio is rated
A
Rated A on Competitive Edge
Rated A on Growth Potential
Rated A on Differentiation

Industries

Biotechnology

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Overview

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their diverse client base includes patients, healthcare providers, and researchers. The company generates revenue through drug development, licensing agreements, and partnerships, with a pipeline of over 15 drug programs targeting 20 genetic diseases. BridgeBio promotes a culture of independent thinking and transparency, facilitating rapid, data-driven decision-making to bring therapies to market more quickly.

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $300M royalty monetization strengthens BridgeBio's financial position.
  • Approval of Beyonttra in Japan marks a significant milestone for BridgeBio.
  • BridgeBio's robust pipeline targets over 20 genetic diseases, enhancing market potential.

What critics are saying

  • Increased competition from Alnylam's Amvuttra may impact BridgeBio's market share.
  • Reliance on royalty monetization deals could indicate potential cash flow challenges.
  • Decentralized model may lead to challenges in strategic direction and resource allocation.

What makes BridgeBio unique

  • BridgeBio employs a unique decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases allows BridgeBio to target well-understood genetic causes.
  • BridgeBio leverages genome sequencing and molecular biology for innovative therapies.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$3288.7M

Above

Industry Average

Funded Over

7 Rounds

Post IPO Convertible funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Convertible Funding Comparison
Coming Soon

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

↓ -1%

1 year growth

↑ 3%

2 year growth

↑ 0%
Wallstreet Online
Jun 30th, 2025
BridgeBio Raises $300M via Royalty Monetization

BridgeBio has secured a $300 million upfront payment by monetizing 60% of its European royalties on the first $500 million of annual BEYONTTRA net sales, with a cap of 1.45x on total payments. This deal with HealthCare Royalty and Blue Owl Capital strengthens BridgeBio's balance sheet and supports the launch of Attruby and its late-stage pipeline. Acoramidis, approved as Attruby in the U.S. and BEYONTTRA in Europe, has shown significant benefits in the ATTRibute-CM study.

Bitcoin Ethereum News
Jun 20th, 2025
Parataxis Korea's $18.5M BTC Strategy

Parataxis Holdings is launching a BTC treasury company in South Korea through a reverse merger with Bridge Biotherapeutics, valued at â‚©25M ($18.5M). The new entity, Parataxis Korea, aims to emulate the BTC strategies of Strategy in the US and Metaplanet in Japan. Bridge Biotherapeutics, previously distressed, saw its stock rise after the BTC strategy shift. Parataxis Capital, affiliated with Parataxis Holdings, is a Tier-4 investment fund with a focus on crypto projects.

Stock Titan
May 12th, 2025
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming presentations at the Heart Failure 2025 conference in Belgrade, Serbia from May 17-20, 2025.

TradingView
May 12th, 2025
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio to present clinical outcomes, Quality of Life measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM study at the Annual Congress of the Heart Failure Association of the ESC.

BioSpace
Mar 29th, 2025
Beyonttra(Tm) (Acoramidis), The First Near-Complete Ttr Stabilizer (>=90%), Approved In Japan To Treat Attr-Cm

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30BridgeBio will receive a $30 million milestone payment from Alexion, AstraZeneca Rare Disease, with royalties in the low double digits on net sales of Beyonttra in JapanPALO ALTO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Japanese Ministry of Health, Labour and Welfare has approved acoramidis, under the brand name Beyonttra, for the treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. Relative increases in serum TTR concentrations resulting from greater TTR stability have been associated with reduced risk of all-cause and cardiovascular mortality in the general population in recent literature.1 ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Alexion, AstraZeneca Rare Disease will be responsible for all commercial activity for Beyonttra in Japan.“There is significant need for new treatment options for ATTR-CM, a progressive, fatal disease, worldwide

Recently Posted Jobs

Sign up to get curated job recommendations

BridgeBio is Hiring for 29 Jobs on Simplify!

Find jobs on Simplify and start your career today

đź’ˇ
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →